New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
14:50 EDTABBV, SHPGAbbVie CEO visited Shire holders, urged them to pressure company, FT says
AbbVie (ABBV) CEO Richard Gonzalez visited with large Shire (SHPG) shareholders, urging them to press Shire to engage in talks and saying that his company would like to see its books before considering a higher offer, according Financial Times, citing people in attendance at the meeting. Reference Link
News For ABBV;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 30, 2015
09:48 EDTABBVAbbVie sees 100bps of gross margin improvement if FX rates are stable
09:35 EDTABBVAbbVie sees high teens revenue growth on an operational basis in FY15
Subscribe for More Information
09:34 EDTABBVAbbVie sees high teens revenue growth on an operational basis in FY15
Subscribe for More Information
09:33 EDTABBVAbbVie sees Q1 adjusted EPS 82c-84c, consensus 85c
09:30 EDTABBVAbbVie confirms FY15 guidance issued earlier this month
Subscribe for More Information
07:50 EDTABBVAbbVie reports Q4 Humira sales up 10.6% to $3.36B
Subscribe for More Information
07:49 EDTABBVAbbVie sees FY15 adjusted EPS $4.25-$4.45, consensus $4.37
Subscribe for More Information
07:48 EDTABBVAbbVie reports Q4 GAAP revenue $5.45B, consensus $5.36B
Subscribe for More Information
07:48 EDTABBVAbbVie reports Q4 adjusted EPS 89c, consensus 86c
Subscribe for More Information
January 29, 2015
15:37 EDTABBVNotable companies reporting before tomorrow's open
Subscribe for More Information
14:46 EDTABBVAbbVie technical comments ahead of earnings, levels to watch
The shares have been trending down since hitting the 52-week high of $70.76 back in early December of last year. At the current price of $63.01, the first important support level to watch on negative news or outlook would be at the 200-day moving average, last at $58.04. A test and a bounce there would be bullish, while a breakdown would be bearish for the longer-term uptrend. Levels to watch below the 200-day are at $56.51, and then at $55.80. If the news is a positive surprise, the first resistance level of note as a potential upside objective is at the $65 area. A breakout above $65 would turn the trend to bullish, with next resistance levels at $67.16, $68.29, and the 52-week high at $70.76.
13:38 EDTABBVEarnings Preview: AbbVie reports Q4 results after FDA Viekira Pak approved
AbbVie (ABBV) is scheduled to report fourth quarter earnings before the market open on Friday, January 30 with a conference call scheduled for 9:00 am ET. EXPECTATIONS: Analysts are looking for earnings per share of 86c on revenue of $5.36B, according to First Call. The consensus range for EPS is 82c-90c on revenue of $5.17B-$5.59B. LAST QUARTER: AbbVie reported third quarter EPS of 89c, considerably higher than consensus estimates of 77c, on revenue of $5.02B against estimates of $4.82B. The company raised its fiscal year 2014 EPS view to $3.25-$3.27 from $3.06-$3.16 against consensus estimates of $3.16. On its Q3 earnings conference call the company said it is "well on track" to exceed original Humira sales forecast for FY14. CEO Richard Gonzalez commented on the quarter, "Our Q3 results reflect the strong performance of our business with double-digit growth from Humira and several other key brands. Our underlying business grew nearly 14% in the quarter excluding lipids, We exceeded our outlook for the quarter and have significantly raised our original 2014 guidance. In Q4, we look forward to the U.S. approval of our interferon-free HCV combination, which will further accelerate sales and earnings growth in 2015 and beyond." STREET RESEARCH: On January 9, BofA/Merrill downgraded AbbVie to Neutral based on valuation with a price target of $70. On January 6, UBS raised its price target on AbbVie shares to $76 from $72, citing increased market share assumptions for the company's Viekira Pak Hep C regimen and a more favorable view of the regimen's approval chances in the EU. The firm maintained its Buy rating on the stock. PRICE ACTION: AbbVie shares are up around 3% since the company's last earnings report on October 31 and are up around 1.5% to $62.83 in midday trading ahead of Friday's earnings release.
January 27, 2015
17:04 EDTSHPGShire granted petitiion by U.S. Supreme Court
Subscribe for More Information
January 26, 2015
08:21 EDTSHPGShire the 'real winner' after NPS gets approval for Natpara, says Janney Capital
Janney Capital said NPS Pharmaceuticals' (NPSP) getting FDA approval for its second marketed product, Natpara, is a positive for NPS, but that the "real winner" is Shire (SHPG), noting that the company had no stipulations dependent on Natpara approval in its deal to buy NPS. The firm expects the acquisition to move forward as planned and maintains its Neutral rating on NPS shares.
07:27 EDTSHPGShire price target raised to $263 from $247 at Jefferies
Subscribe for More Information
05:26 EDTSHPGShire SHP609 receives FDA fast track designation
Subscribe for More Information
January 25, 2015
12:30 EDTSHPGShire comments on press release from NPS Pharma on Natpara approval
Subscribe for More Information
January 22, 2015
05:27 EDTSHPGShire reports positive response from European DCP for Elvanse Adult
Subscribe for More Information
January 20, 2015
14:06 EDTSHPGCitizens, Keysight identified as long positions by Einhorn
Subscribe for More Information
08:10 EDTSHPGShire price target raised to $247 from $228 at Jefferies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use